| Mature B-Cell Non-Hodgkin Lymphoma studied in …STUDIED_INderived200 of 2,506show all (up to 200) |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | ALK-Positive Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05952024Phase 2 · recruiting Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337318Phase 3 · recruiting Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Classic Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06977711Phase 1 · recruiting Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006518recruiting Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00923507recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04269902Phase 3 · recruiting Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06252675Phase 2 · recruiting Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625203active not recruiting A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06697184Phase 1/Phase 2 · recruiting A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06742996Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06943872Phase 3 · recruiting A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973187Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03349450Phase 2 · completed DPX-Survivac and Checkpoint Inhibitor in DLBCL · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03460977Phase 1 · recruiting A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594642Phase 1 · active not recruiting A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05023980Phase 3 · active not recruiting A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05139017Phase 2/Phase 3 · recruiting A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907759Phase 2 · recruiting Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05963074Phase 2 · active not recruiting A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06091865Phase 3 · recruiting A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284122Phase 3 · active not recruiting Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06717347Phase 3 · recruiting A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929624Phase 3 · active not recruiting A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07519772Phase 1/Phase 2 · recruiting A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634471Phase 2/Phase 3 · recruiting A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07709000Phase 2 · not yet recruiting A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04728893Phase 2 · recruiting Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) · condition mapped PROBABILISTIC · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840602Phase 2 · recruiting Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05947851Phase 3 · recruiting A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06136559Phase 3 · recruiting A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548450Phase 2 · not yet recruiting Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03463057Phase 2 · active not recruiting The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04662255Phase 3 · active not recruiting Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553872Phase 2 · recruiting Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07783594Phase 2 · not yet recruiting Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00039676active not recruiting Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03226704enrolling by invitation Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03628612Phase 2 · enrolling by invitation Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05471843Phase 1/Phase 2 · active not recruiting Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05861050Phase 1/Phase 2 · suspended Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Blastoid Variant Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218341Phase 4 · recruiting A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226843Phase 1 · recruiting A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01829958NA · active not recruiting Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05296070Phase 2 · recruiting Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029309Phase 1/Phase 2 · recruiting Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06549595Phase 3 · recruiting A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594798Phase 2 · active not recruiting A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Indolent B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07422610Phase 1 · recruiting Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221500Phase 2 · recruiting A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341191Phase 2 · recruiting Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446236Phase 1 · active not recruiting Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02629809Phase 2 · active not recruiting Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04002947Phase 2 · recruiting Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05757219Phase 2 · recruiting Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07343934Phase 1 · recruiting huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04094311Phase 3 · recruiting Study of Out of Specification for Tisagenlecleucel · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06647732Phase 2 · active not recruiting Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02180724Phase 2 · active not recruiting An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02558816Phase 1/Phase 2 · completed A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03267433Phase 3 · active not recruiting Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04115631Phase 2 · active not recruiting A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246086Phase 1/Phase 2 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Classic Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07739459Phase 2 · not yet recruiting Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07817641NA · recruiting Proton Therapy for Mediastinal Lymphoma (PROMLY) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07818499Phase 1/Phase 2 · not yet recruiting A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819396Phase 2 · not yet recruiting Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451810Phase 2 · active not recruiting A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05578976Phase 3 · active not recruiting A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934084NA · recruiting Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06091254Phase 3 · recruiting A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06291220Phase 1 · active not recruiting A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06492837Phase 2 · active not recruiting Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06526793Phase 2 · recruiting Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061951Phase 2 · recruiting Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910583Phase 2 · completed Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04169737Phase 2 · recruiting Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04759586Phase 3 · active not recruiting Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05272384Phase 1 · recruiting Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570017Phase 1 · recruiting A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07799220Phase 2 · not yet recruiting A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01827605Phase 3 · completed A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04542824Phase 1/Phase 2 · active not recruiting Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04623541Phase 1/Phase 2 · active not recruiting Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04663347Phase 1/Phase 2 · active not recruiting Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04915248Phase 2 · recruiting Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326308recruiting Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003295Phase 2 · recruiting Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07387471Phase 2 · active not recruiting Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07808827Phase 3 · not yet recruiting A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03666000Phase 1 · recruiting Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05929222Phase 3 · recruiting Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564038Phase 1/Phase 2 · recruiting A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06767891enrolling by invitation Real-world Study of Acalabrutinib · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07200375recruiting An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01695941Phase 1 · active not recruiting Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680052Phase 3 · active not recruiting A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043323Phase 2 · recruiting A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03824483Phase 2 · active not recruiting Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624906Phase 2 · active not recruiting Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05533775Phase 1/Phase 2 · recruiting A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mature B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05951959Phase 2 · active not recruiting A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05976763Phase 3 · recruiting Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07154823recruiting A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01961063Phase 1 · active not recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | AIDS-Related Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561347Phase 2 · recruiting Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029737Phase 2 · recruiting A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332507Phase 1 · recruiting Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791498Phase 2 · not yet recruiting Teclistamab In Waldenstrom's Macroglobulinemia · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06108232Phase 2 · recruiting Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07516093Phase 3 · recruiting Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07734038Phase 2 · recruiting Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02048813Phase 3 · active not recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03701282Phase 3 · active not recruiting Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737981Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04477486Phase 2 · completed Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802590Phase 2 · active not recruiting Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05512390Phase 1 · active not recruiting A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06687772Phase 2 · recruiting CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365306Phase 2 · recruiting Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07520006Phase 1/Phase 2 · recruiting Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03521596completed Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05836896Phase 1 · recruiting A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959698Phase 1 · active not recruiting Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02911142Phase 1/Phase 2 · active not recruiting Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03190928recruiting Clonal Evolution in Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06112847Phase 2 · active not recruiting Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06227026Phase 1 · recruiting Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788118Phase 1/Phase 2 · recruiting A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626791Phase 2 · active not recruiting Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04742387active not recruiting Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594939Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07784101Phase 3 · not yet recruiting A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05249959Phase 2 · active not recruiting Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441214active not recruiting Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06970743Phase 3 · active not recruiting A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02160015Phase 1 · active not recruiting Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884998Phase 1 · active not recruiting Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05458297Phase 2 · active not recruiting A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428707early Phase 1 · recruiting Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04007029Phase 1 · active not recruiting Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792502Phase 2 · recruiting Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07777120active not recruiting Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390869Phase 3 · active not recruiting Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02966756Phase 2 · active not recruiting A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04104776Phase 1/Phase 2 · recruiting A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06781359recruiting Study on Plasmablastic Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07588698Phase 2 · not yet recruiting Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma · condition mapped ALIAS · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774234Phase 2 · not yet recruiting Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774390recruiting Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04880434Phase 2 · completed Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03943901Phase 2 · active not recruiting Split-Dose R-CHOP for Older Adults With DLBCL · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254743Phase 3 · recruiting A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06927466Phase 1 · recruiting A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07673367Phase 2 · recruiting Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843294Phase 1 · active not recruiting Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma · condition mapped CURATED_BROADER · 2,506 trials mapped (911 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662928Phase 2 · not yet recruiting Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · condition mapped ONTOLOGY_EXACT · 2,506 trials mapped (911 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |